Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Return on Sales: 2020-2023

Historic Return on Sales for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to -2.90%.

  • ADC Therapeutics' Return on Sales fell 192.00% to -2.90% in Q3 2023 from the same period last year, while for Sep 2023 it was -2.90%, marking a year-over-year decrease of 192.00%. This contributed to the annual value of -0.73% for FY2022, which is 732.00% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Return on Sales is -2.90%, which was down 107.90% from -1.40% recorded in Q2 2023.
  • ADC Therapeutics' 5-year Return on Sales high stood at 0.01% for Q2 2020, and its period low was -18.30% during Q3 2021.
  • Over the past 3 years, ADC Therapeutics' median Return on Sales value was -1.58% (recorded in 2023), while the average stood at -4.30%.
  • In the last 5 years, ADC Therapeutics' Return on Sales crashed by 1,830bps in 2021 and then skyrocketed by 1,732bps in 2022.
  • Over the past 4 years, ADC Therapeutics' Return on Sales (Quarterly) stood at 0.00% in 2020, then crashed by 1,830bps to -16.59% in 2021, then surged by 1,562bps to -0.98% in 2022, then slumped by 192bps to -2.90% in 2023.
  • Its Return on Sales stands at -2.90% for Q3 2023, versus -1.40% for Q2 2023 and -1.58% for Q1 2023.